CLINDESSE (clindamycin phosphate) by Design Pharmaceuticals is [see clinical pharmacology, microbiology ()] . First approved in 2004.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
CLINDESSE is a vaginal cream formulation of clindamycin phosphate, a lincosamide antibiotic approved in 2004 for vaginal infections. It works by inhibiting bacterial protein synthesis, with mechanism of action detailed in clinical pharmacology documentation. The product is indicated for vaginal bacterial infections in women.
Product approaching loss of exclusivity with minimal Medicare spending; brand team likely focused on defending share against generics rather than growth initiatives.
[see Clinical Pharmacology, Microbiology ()] .
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris
W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers
Worked on CLINDESSE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
CLINDESSE offers limited career growth given immediate LOE and minimal linked job postings; roles are primarily defensive and operationally focused. Joining this product now is suitable only for professionals seeking experience in generic transition management or end-of-life brand stewardship.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo